March 29, 2017 / 11:15 AM / in 8 months

BRIEF-Immunovaccine announces positive interim clinical data from Ovarian cancer study

March 29 (Reuters) - Immunovaccine Inc:

* Immunovaccine announces positive interim clinical data from ovarian cancer study of DPX-survivac in combination with epacadostat

* Immunovaccine Inc - based on interim analysis, combination therapy appears to have an acceptable safety profile

* Immunovaccine - at time of interim analysis, 3 of 4 patients exhibited stable disease, while fourth patient continued to progress and discontinued trial

* Immunovaccine Inc - expects to complete enrollment and issue topline data by end of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below